Apellis Pharmaceuticals (APLS) reported positive results from a Phase 3 clinical trial, PEGASUS, evaluating pegcetacoplan (APL-2) in adults with paroxysmal nocturnal hemoglobinuria. The trial pitted the drug directly against Alexion's Soliris and offered positive results. As per the results of the trial, Apellis is now in a position to take on Alexion, subject to regulatory approvals.
The phase 3 involved 80 PNH patients who suffered from anemia despite being on Soliris. The patients were then randomized and either received Soliris or the Apellis inhibitor. After 16 weeks, patients on pegcetacoplan showed an